Core Viewpoint - A-share listed companies are actively engaging in shareholder return activities, utilizing methods beyond cash dividends, such as offering products, services, discount coupons, or exclusive rights, with mixed market performance but overall outpacing the CSI 300 index [1] Group 1: Shareholder Return Activities - Approximately 130 companies have shown varied market performance, with some adopting creative ways to reward shareholders [1] - Companies are not only providing gifts but are also formulating future dividend plans, with 10 companies announcing shareholder return strategies for the next three years [1] Group 2: Dividend Plans and Performance - The top performers in terms of stock price increase since 2025 include Haoen Qidian (301488) with a rise of 205.66%, Shuiyang Co. (300740) at 87.59%, and Huasheng Co. (600156) at 69.18% [3] - Specific dividend plans include: - Haoen Qidian: Minimum 10% of distributable profit annually from 2025 to 2027 [3] - Shuiyang Co.: Cash dividends not less than 10% of distributable profit annually from 2025 to 2027 [3] - Huasheng Co.: Cumulative cash distribution of at least 30% of the average distributable profit over the last three years from 2026 to 2028 [3] - Other companies like Gais Food (36.36%) and Bona Film (34.26%) also have significant dividend commitments [3]

Company Dynamics - The company announced on January 15 that its "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" has been approved as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness through a recombinant collagen and hyaluronic acid composite solution [1] - The approval of this product is expected to further expand the company's aesthetic medicine product matrix and validate its leading technological research and development capabilities [1] Comments - The approval of the world's first recombinant collagen and hyaluronic acid composite solution for improving cheek smoothness represents the second medical aesthetic license obtained by the company [2] - The company plans to steadily advance the product's market launch and promotion through a diverse product portfolio, comprehensive channel network, and refined brand operations, aiming to strengthen its leading market position in the health and beauty sector [2] Future Prospects - The company has a rich pipeline of aesthetic medicine products, with the cross-linked neck wrinkle product having received national priority review qualification, and the cross-linked nasolabial fold product progressing smoothly [2] - The successful approval of the first two aesthetic products has validated the company's technological leadership and safety, with strong channel resources and operational experience expected to facilitate the rollout of future products [2] Cosmetics Product Matrix and Channel Expansion - The company has a clear plan for its cosmetics product matrix and channel expansion, with a rich reserve of new products, including multiple new offerings from the 可复美胶原修护, 焦点, and 秩序 series planned for launch [2] - The company is also upgrading its 可丽金 brand and plans to introduce new products by 2026, while collaborating with key influencers like Li Jiaqi to enhance marketing efforts [2] - The company aims to strengthen its online presence through influencer partnerships and expand its offline coverage in cinema lines, OTC, and CS/KA channels, as well as its own store layout [2] Profit Forecast and Valuation - The company maintains its net profit forecast for 2025-2026 and introduces a net profit estimate of 2.4 billion for 2027, with the current stock price corresponding to a 16x and 14x P/E for 2026-2027 [2] - The company maintains an outperform rating and a target price of 56 HKD, corresponding to a 25x and 23x P/E for 2026-2027, indicating a potential upside of 55% [2]

Core Viewpoint - The company Mao Ge Ping (01318) has received a filing notice from the China Securities Regulatory Commission regarding the implementation of full circulation of H-shares, effective from January 13, 2026 [1] Group 1 - The company has completed the filing for a total of 228 million unlisted shares for H-share full circulation with the China Securities Regulatory Commission [1] - The filing notice is valid for 12 months from January 13, 2026 [1] - The company will apply to the Stock Exchange of Hong Kong for approval of the related H-share listing and trading [1]

Group 1 - Shandong Huawutang Cosmetics Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange [1] - The exclusive sponsor for the listing is CITIC Securities [1]

Group 1 - Shandong Huawutang Cosmetics Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange [1]

Core Viewpoint - Shandong Huawutang Cosmetics Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor, indicating a significant step towards public offering in the cosmetics sector [1] Company Overview - Huawutang is recognized as a rapidly growing Chinese skincare and personal care brand, known for its multi-category expansion and strong market presence [1] - The company has evolved from a single star product to a comprehensive product matrix that includes body, hair, and facial care, establishing itself as a leading domestic brand in multiple categories within the Chinese skincare and personal care market [1] Market Position - According to Frost & Sullivan, Huawutang is projected to be the leading domestic brand in body lotion, body scrub, and facial cleansing mousse by retail sales in 2024 [1]

智通财经APP获悉，据港交所1月16日披露，山东花物堂化妆品股份有限公司(简称：花物堂)向港交所主 板递交上市申请书，中信证券为其独家保荐人。招股书显示，公司是半亩花田(Dream Garden)，一个因 持续高速增长、多品类拓展而在行业中脱颖而出的中国皮肤及个人护理品牌。花物堂从单一明星产品逐 步拓展至涵盖身体、发部和面部洗护的全品类矩阵，成为少数能够在中国皮肤及个人护理市场的多个品 类均实现领先地位的国货品牌。根据弗若斯特沙利文的资料，以2024年零售额计，公司是身体乳、身体 磨砂膏、洁面慕斯的国货第一品牌。 ...

Group 1 - The cosmetics sector experienced a decline of 0.63% on January 16, with Jinsheng New Materials leading the drop [1] - The Shanghai Composite Index closed at 4101.91, down 0.26%, while the Shenzhen Component Index closed at 14281.08, down 0.18% [1] - Key stocks in the cosmetics sector showed varied performance, with Jiaheng Jiahua rising by 3.44% to a closing price of 39.37, while Jinsheng New Materials fell by 5.09% to 17.54 [2] Group 2 - The net outflow of main funds in the cosmetics sector was 89.97 million yuan, while retail investors saw a net inflow of 82.30 million yuan [2] - The main fund inflow for key stocks included 28.22 million yuan for Proya, while Jinsheng New Materials had a net outflow of 3.97 million yuan [3] - Retail investors showed a significant net inflow in stocks like Jiaheng Jiahua and Beitaini, while Jinsheng New Materials and Shanghai Jahwa experienced outflows [3]

中国质量新闻网讯 2026年1月1日起，根据《化妆品监督管理条例》第七十八条规定，育发、脱毛、美乳、健美、除臭五类 原特殊用途化妆品的5年过渡期正式届满，此类产品不得再进行生产、进口和销售。近日，江苏省泰州市姜堰区市场监管 局组织执法力量对全区15家商场超市、化妆品专营店、美容美发店等开展化妆品专项监督检查行动。 全面排查禁售产品，严审标签合规细节。执法人员以对货架、仓库及线上销售后台开展拉网式排查，清理五类过渡期届满 后的禁售产品。同时，严格核查产品标签标识信息，细致查验是否存在"国妆特制字G/国妆特进字J+四位年份自然数+四位 注册顺序数"等原特殊化妆品注册文号，坚决杜绝伪造、变造注册文号、篡改标签信息等违法违规行为。 精准核查分类产品，筑牢全链合规防线。针对过渡期后调整的两类产品实施差异化监管：一方面，对已按普通化妆品管理 的产品，重点核查备案状态及有效性、信息一致性、包装标注规范性，确保产品从备案到销售全流程合规；另一方面，对 需纳入药品管理的高风险产品，严格检查是否违规以化妆品名义销售、是否取得药品注册并标注批准文号，遏制"药妆混 淆""以妆代药"等行为。 深化法规宣贯指导，引导主体主动守规。执法人 ...

Core Viewpoint - Company maintains a "outperforming the industry" rating for Giant Bio (02367) with a target price of HKD 56, indicating a potential upside of 55% based on 26-27 P/E ratios of 25x and 23x respectively, supported by strong R&D capabilities, brand recognition, and team cohesion [1] Recent Events - The company announced on January 15 that its "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" has been approved as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness [2][3] - The approval is expected to expand the company's aesthetic product matrix and validate its leading technological R&D capabilities [2] Future Product Pipeline - The company has a rich pipeline of aesthetic products, including cross-linked neck wrinkle products that have received priority review status and cross-linked nasolabial fold products that are progressing smoothly [3] - The approval of the first two aesthetic products has confirmed the company's technological leadership and safety, with strong channel resources and operational experience that can be reused for future product launches [3] Cosmetics Product Matrix and Channel Expansion - The company has a clear plan for product and channel expansion, with a rich reserve of new products including the "Kefumei Collagen Repair," "Focus," and "Order" series set to launch [4] - The company plans to upgrade the "Keli Jin" brand and introduce new products by 2026, while also enhancing collaboration with key influencers like Li Jiaqi for promotional activities [4] - There is a focus on strengthening online influencer networks and self-operated teams, as well as expanding offline channels including cinema lines, OTC, and CS/KA channel coverage [4]